Trial Profile

Clinical trial of MEDI 5117 as a potential therapy for rheumatoid arthritis.

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 20 Jan 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ziltivekimab (Primary)
Indications Rheumatoid arthritis
Focus Adverse reactions

Most Recent Events

18 Jan 2017 According to WuXi AppTec media release, an Investigational New Drug (IND) application of WBP216 (MEDI5117) for rheumatoid arthritis (RA) and other autoimmune disorders has been approved by the China Food and Drug Administration (CFDA).
31 Mar 2015 New trial record
27 Mar 2015 An IND has been accepted for review by the China Food and Drug Administration, according to a WuXi PharmaTech media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com